Following the first two articles that discussed the treatment of cancer and pain, this third piece will focus on the use of cannabinoids to treat psoriasis and rheumatoid arthritis.
Dr. Frank D'Ambrosio, CMO of Block Commodities Plc, provides an insight into the UK’s medical cannabis industry.
Katharina Zedlacher, PR and communications at BioBloom GmbH, details the recent studies conducted to highlight how cannabinoid CBDa (cannabidiolic acid) increases bioavailability of CBD and its health-promoting properties.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health (NIH), shares his thoughts on closing gaps in cannabinoid research to make progress in pain management.
Gregory Land, CEO at Canna CBD Limited, highlights the dangers of purchasing cannabidiol (CBD) from an unreputable source.
John Wallace, Managing Director at Mile High Labs International, Ltd. explores the market of CBD in food and beverages, including regulation.
Paul McCourt, CEO and Founder of Celtic Wind Crops, outlines his vision for the future when it comes to how growing hemp in the local community can help a global crisis.
In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
Liam McGreevy, CEO of Ethnopharm Ltd, explains his thoughts on creating value in today’s maturing cannabis market, including how the firm can help both new and established businesses make sense of this.
Here, Christoph Schubert discusses how light is one of the most important factors in the professional cultivation of medical cannabis.
Chris Gunning, General Manager – Accreditation Services at A2LA, discusses the value of accreditation in today’s cannabis industry.
Farrukh Saleem, Head of Sales & Marketing at Winchester MD, explains why the company is ahead of the curve when it comes to today’s market for CBD products.
Jersey Hemp share that they have been granted the first licence in the British Isles to harvest hemp flowers for CBD, in this article.
Here, OilsBySimpson Founder Kevin Simpson and Clinical Professor, Consultant Physician and Research Director, Filip Krag Knop, explain what we know so far about CBD’s effect on Type 2 diabetes and why running a clinical trial is so important.
Content Marketing Specialist, Tammy Taylor details how CBD can be used to treat multiple sclerosis (MS) in this article.
Here, Keeley Berry, Nutritional Expert and Product Developer at BetterYou, answers the most commonly asked questions about CBD.
Jade Mansfield from The British CBD Company, provides an insight into the CBD drinks market with a focus on trends, investments and drawbacks.
Recent research commissioned by the Centre for Medicinal Cannabis has revealed that the UK CBD market is worth £300 million.
Here, content director Joseph at TheAmsterdam.com, discusses the effects of cannabidiol on the brain.
DragonflyCBD has conducted research into the effects of CBD oil in aiding stress and anxiety, here they discuss their findings.